Αρχική World News Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with... World News Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy Από Ogkologos - 28 Σεπτεμβρίου, 2026 97 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TAISHAN-302 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR iDFS Benefit with Ribociclib Plus Nonsteroidal Aromatase Inhibitor in Patients with... 14 Νοεμβρίου, 2024 New on NCI’s Websites for December 2023 28 Δεκεμβρίου, 2023 Scientists Discover How Air Pollution May Trigger Lung Cancer in Never-Smokers... 10 Σεπτεμβρίου, 2022 FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC 24 Ιουνίου, 2026 Φόρτωση περισσοτέρων HOT NEWS Investing in volunteers since 2002: The tale of time ESMO Welcomes the WHO Global Status Report on Cancer with Key... 6 of the biggest good news cancer stories of 2021 Cancer Moonshot℠ Workshop Highlights Recent Research Advances
